Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

KlotoDx

Financiado

Cerrado

KlotoDx A quick and cost effective near patient tool to identify sepsis related...

KlotoDx A quick and cost effective near patient tool to identify sepsis related bacteria and antibiotic resistances Sepsis is a common disease caused mostly by bacteria that affects about 30 M people each year worldwide. If not diagnosed on time and treated appropriately, it may be lethal in 30% of cases and the cost for the healthcare system i... ver más

31/12/2018

MOIRAI BIODESIGN

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

MOIRAI BIODESIGN Biotecnologia e investigacion. desarrollo de terapias genicas y de metodos de diagnostico. prestacion de servicios para empresas biofarmaceu...

TRL 4-5 | 166K€

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-12-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

MOIRAI BIODESIGN

50.00K€ | Lider

MECANICA CAPE

883.35K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SMARTDIAGNOS Next generation sepsis diagnosis 5M€ Cerrado

FIT-SEP Fully integrated technology for predictive diagnosis of seps... 197K€ Cerrado

ACUSEP Integrated whole blood acoustophoresis and homogeneous nucle... 4M€ Cerrado

TAILORED-TREATMENT DEVELOPMENT OF TAILORED ANTIMICROBIAL TREATMENT REGIMENS AND... 8M€ Cerrado

RAPP-ID Development of RApid Point of Care test Platforms for Infect... 16M€ Cerrado

RAPID-SEP-AST Rapid diagnostic for bacterial SEPSIS and AMR urgently neede... 4M€ Cerrado

Duración del proyecto: 4 meses Fecha Inicio: 2018-08-01
Fecha Fin: 2018-12-31

Líder del proyecto

MOIRAI BIODESIGN Biotecnologia e investigacion. desarrollo de terapias genicas y de metodos de diagnostico. prestacion de servicios para empresas biofarmaceu...

TRL 4-5 | 166K€

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Sepsis is a common disease caused mostly by bacteria that affects about 30 M people each year worldwide. If not diagnosed on time and treated appropriately, it may be lethal in 30% of cases and the cost for the healthcare system if not detected within the first 24 hours can rise dramatically. Current diagnostic techniques used to detect bacteria in patients’ blood, and identify their antimicrobial resistances, are still based on blood culture which takes more than 1 day and has a very limited detection efficiency. Moirai Biodesign is currently engineering a whole new generation of RNA-based diagnostics using both our in-house and cutting-edge artificial intelligence algorithms to detect ribosomal RNA from bacterial agents and expressed bacterial genes associated to common antibiotic resistances and a patient’s blood sample. Our platform is a near-patient, fast, efficient and cost-effective solution for the early detection and characterization of sepsis-related bacteria which will improve patient’s treatment, avoid broad-spectrum antibiotics’ side-effects and dramatically reduce death rates. Our technology has been preliminary validated for the diagnosis of Acute Promyelocytic Leukemia (APL) and KlotoDx’s main goal is to further adapt, validate and commercialize our disruptive diagnosis device for the identification of sepsis-causing bacteria and their antibiotic resistance genes. To achieve it and place our disruptive near-patient solution in the healthcare market, we envision a total investment of around €2.3 M and we plan to reach the 70% (around €1.6M) by applying for a Phase 2 within the H2020 SME-Instrument programme, once we perform the feasibility study during Phase 1. The increasing need for early sepsis diagnosis aand its characterization in terms of antibiotic resistance boosts KlotoDx’s opportunity to enter the primary care segment in a very disruptive manner.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores